JR
Distinguished in Metastatic Brain Tumor

Dr. Jeffrey J. Raizer

Northwestern Medicine Lou And Jean Malnati Brain Tumor Institute
Chicago, IL
Distinguished
 in Metastatic Brain Tumor
Specialties:Hematology Oncology | Neurology
Experience:32 Years
Clinical Trials:Currently Recruiting for 1 Trial
Accepts:New PatientsMedicare
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Jeffrey J. Raizer's experience treating your condition:
About Dr. Jeffrey J. Raizer

Jeffrey Raizer is a Hematologist Oncology specialist and a Neurologist in Chicago, Illinois. Raizer has been practicing medicine for over 32 years and is rated as a Distinguished expert by MediFind in the treatment of Metastatic Brain Tumor. He is also highly rated in 19 other conditions, according to our data. His top areas of expertise are Glioma, Astrocytoma, Glioblastoma, Brain Tumor, and Bone Marrow Transplant. He is licensed to treat patients in Illinois. Raizer is currently accepting new patients.

His clinical research consists of co-authoring 104 peer reviewed articles and participating in 19 clinical trials in the past 15 years. In particular, he has co-authored 12 articles in the study of Metastatic Brain Tumor.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Jeffrey J. Raizer it is best to call his office and ask if your insurance is accepted.

Accepts Medicare
Call to see if your plan is accepted.
Locations
675 N Saint Clair St, Chicago, IL 60611
Background & Education
Graduate Institution
New York Medical College, 1991
Specialties
Hematology Oncology
Neurology
Licenses
Psychiatry & Neurology in IL
Hospital Affiliations
Northwestern Medicine Lake Forest Hospital
Northwestern Memorial Hospital
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials
A Phase 2, Single Arm, Multi-center, Open Label Trial Combining Optune With Concurrent Bevacizumab in the Setting of Recurrent or Progressive Meningioma
Enrollment Status: Recruiting
Publish Date: May 27, 2022
Intervention Type: Procedure, Device, Biological
Study Phase: Phase 2
A Phase II, Open Label, Clinical Trial Of Pre-Surgical and Adjuvant Treatment of Recurrent Malignant Glioma With Tremelimumab and Durvalumab (MEDI4736) Alone and in Combination to Determine Immunologic Changes From Treatment
Enrollment Status: Completed
Publish Date: April 18, 2022
Intervention Type: Biological, Procedure, Other
Study Drugs: DurvalumabTremelimumab
Study Phase: Phase 2
A Pharmacokinetic Study of Pemetrexed in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases
Enrollment Status: Completed
Publish Date: September 08, 2021
Intervention Type: Drug
Study Drug: Pemetrexed
Study Phase: Early Phase 1
Phase I Trial of Radiation Therapy Plus Temozolomide With MK-3475 in Patients With Newly Diagnosed Glioblastoma (GBM)
Enrollment Status: Terminated
Publish Date: October 28, 2020
Intervention Type: Other, Drug, Radiation, Biological
Study Phase: Phase 1
A Phase II Study of the Efficacy of Hypofractionated Radiation Therapy With Bevacizumab and Temozolomide Followed by Maintenance Temozolomide and Bevacizumab for Recurrent High-Grade Gliomas
Enrollment Status: Terminated
Publish Date: March 12, 2020
Intervention Type: Radiation, Drug, Biological, Other
Study Phase: Phase 2
A Phase I/II Trial of Arsenic Trioxide and Temozolomide in Combination With Radiation Therapy for Patients With Malignant Gliomas
Enrollment Status: Unknown status
Publish Date: February 25, 2020
Intervention Type: Drug, Radiation
Study Drugs: Arsenic TrioxideTemozolomide
Study Phase: Phase 1/Phase 2
A Phase II Safety Study of Bevacizumab in Patients With Multiple Recurrent or Progressive Malignant Gliomas
Enrollment Status: Completed
Publish Date: February 07, 2020
Intervention Type: Biological
Study Phase: Phase 2
Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer
Enrollment Status: Completed
Publish Date: September 26, 2019
Intervention Type: Radiation
Study Phase: Phase 1/Phase 2
A Phase II Trial of Bevacizumab in Patients With Recurrent Solid Tumor Brain Metastases Who Have Failed Whole Brain Radiation Therapy
Enrollment Status: Completed
Publish Date: September 17, 2019
Intervention Type: Procedure, Biological
Study Phase: Phase 2
A Phase II Trial of PTK-787 in Recurrent or Progressive Meningiomas
Enrollment Status: Completed
Publish Date: October 26, 2018
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Study of Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma Without MGMT Promoter Methylation
Enrollment Status: Completed
Publish Date: October 26, 2018
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Trial Evaluating the Effects of Bortezomib in Patients With Recurrent Malignant Gliomas Treated Prior to Surgery and Then Bortezomib and Temozolomide Post-operatively
Enrollment Status: Completed
Publish Date: January 13, 2014
Intervention Type: Drug
Study Phase: Phase 2
A Pilot Study of the Efficacy of Levetiracetam in Patients With Seizures From Brain Metastases
Enrollment Status: Withdrawn
Publish Date: May 18, 2012
Intervention Type: Drug, Procedure
Study Phase: Not Applicable
A Pilot Study Incorporating Motexafin Gadolinium (MGd) Into High-dose Methotrexate (MTX)-Based Chemo-immunotherapy and Radiation for Patients With Newly Diagnosed Primary CNS Lymphoma
Enrollment Status: Withdrawn
Publish Date: May 18, 2012
Intervention Type: Drug, Radiation, Biological
Study Phase: Early Phase 1
A Phase I/II Trial of Cloretazine® (VNP40101M) and Temodar® (Temozolomide) for Patients With Malignant Glioma in First Relapse or Progression
Enrollment Status: Terminated
Publish Date: August 26, 2011
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1/2 Multi-Center, Safety and Efficacy Study Evaluating Intravenously Administered 131I-TM601 in Patients With Progressive and/or Recurrent Malignant Glioma
Enrollment Status: Unknown status
Publish Date: July 17, 2009
Intervention Type: Drug
Study Drug: 131I-TM601
Study Phase: Phase 1/Phase 2
A Phase I Imaging and Safety Study of Intravenous 131-I-TM-601 Labeled Chlorotoxin in Patients With Recurrent or Refractory Somatic and/or Cerebral Metastatic Solid Tumors
Enrollment Status: Completed
Publish Date: March 31, 2009
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1b/2a, Multicenter, Open-Label Study of AQ4N in Combination With Radiation Therapy and Temozolomide, to Evaluate the Safety, Tolerability, and Efficacy in Subjects With Newly Diagnosed Glioblastoma Multiforme
Enrollment Status: Unknown status
Publish Date: May 30, 2007
Intervention Type: Drug, Procedure
Study Drugs: AQ4NTemozolomide
Study Phase: Phase 1/Phase 2
View 17 Less Clinical Trials -
104 Total Publications
NRG Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 19, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
RS
Dr. Roger Stupp
Hematology Oncology | Neurology
Elite
Highly rated in
15
conditions
Hematology Oncology
Neurology

Northwestern Medicine

Northwestern Medicine Lou And Jean Malnati Brain Tumor Institute

675 N Saint Clair St, 
Chicago, IL 

Roger Stupp is a Hematologist Oncology specialist and a Neurologist in Chicago, Illinois. Stupp has been practicing medicine for over 36 years and is rated as an Elite expert by MediFind in the treatment of Metastatic Brain Tumor. He is also highly rated in 15 other conditions, according to our data. His top areas of expertise are Astrocytoma, Glioblastoma, Glioma, and Gliomatosis Cerebri. He is licensed to treat patients in Illinois. Stupp is currently accepting new patients.

RL
Dr. Rimas V. Lukas
Hematology Oncology | Neurology
Elite
Highly rated in
34
conditions
Hematology Oncology
Neurology

Northwestern Medicine

Northwestern Medicine Primary And Specialty Care Lavin Family Pavilion

259 E Erie St, 
Chicago, IL 
 0.1 mi

Rimas Lukas is a Hematologist Oncology specialist and a Neurologist in Chicago, Illinois. Lukas has been practicing medicine for over 21 years and is rated as an Elite expert by MediFind in the treatment of Metastatic Brain Tumor. He is also highly rated in 34 other conditions, according to our data. His top areas of expertise are Glioma, Glioblastoma, Brain Tumor, Astrocytoma, and Gamma Knife Radiosurgery. He is licensed to treat patients in Illinois. Lukas is currently accepting new patients.

PK
Dr. Priya U. Kumthekar
Hematology Oncology | Neurology
Distinguished
Highly rated in
25
conditions
Hematology Oncology
Neurology

Northwestern Medicine

Northwestern Medicine Lou And Jean Malnati Brain Tumor Institute

675 N Saint Clair St, 
Chicago, IL 

Priya Kumthekar is a Hematologist Oncology specialist and a Neurologist in Chicago, Illinois. Kumthekar has been practicing medicine for over 16 years and is rated as an Elite expert by MediFind in the treatment of Metastatic Brain Tumor. She is also highly rated in 25 other conditions, according to our data. Her top areas of expertise are Brain Tumor, Glioblastoma, Glioma, and Astrocytoma. She is licensed to treat patients in Illinois. Kumthekar is currently accepting new patients.